$41.50
1.24% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US74366E1029
Symbol
PTGX
Sector
Industry

Protagonist Therapeutics, Inc. Stock price

$41.50
+5.29 14.61% 1M
+10.23 32.72% 6M
+18.57 80.99% YTD
+21.72 109.81% 1Y
-7.38 15.10% 3Y
+25.94 166.71% 5Y
+29.80 254.70% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.52 1.24%
ISIN
US74366E1029
Symbol
PTGX
Sector
Industry

Key metrics

Market capitalization $2.44b
Enterprise Value $1.89b
P/E (TTM) P/E ratio 15.80
EV/FCF (TTM) EV/FCF 8.19
EV/Sales (TTM) EV/Sales 5.93
P/S ratio (TTM) P/S ratio 7.66
P/B ratio (TTM) P/B ratio 4.50
Revenue (TTM) Revenue $319.12m
EBIT (operating result TTM) EBIT $152.24m
Free Cash Flow (TTM) Free Cash Flow $230.85m
Cash position $564.00m
EPS (TTM) EPS $2.63
P/E forward 20.53
P/S forward 8.58
EV/Sales forward 6.64
Short interest 5.34%
Show more

Is Protagonist Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Protagonist Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Protagonist Therapeutics, Inc. forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Protagonist Therapeutics, Inc. forecast:

Buy
100%

Financial data from Protagonist Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
319 319
-
100%
- Direct Costs 3.37 3.37
22% 22%
1%
316 316
11,540% 11,540%
99%
- Selling and Administrative Expenses 33 33
29% 29%
10%
- Research and Development Expense 127 127
9% 9%
40%
156 156
208% 208%
49%
- Depreciation and Amortization 3.37 3.37
22% 22%
1%
EBIT (Operating Income) EBIT 152 152
203% 203%
48%
Net Profit 170 170
224% 224%
53%

In millions USD.

Don't miss a Thing! We will send you all news about Protagonist Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Protagonist Therapeutics, Inc. Stock News

Neutral
Accesswire
5 days ago
NEWARK, CA / ACCESSWIRE / September 3, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
Neutral
Accesswire
about one month ago
JNJ-2113 Phase 3 ICONIC-LEAD and Phase 3 ICONIC-TOTAL clinical trials in moderate-to-severe plaque psoriasis expected to complete the primary endpoint portion of the studies in Q4 2024 JNJ-2113 Phase 2b ANTHEM clinical trial in moderate-to-severe ulcerative colitis expected to complete the primary endpoint portion of the study in Q4 2024 Rusfertide Phase 2 REVIVE study long-term follow-up data ...
Neutral
Accesswire
about one month ago
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space NEWARK, CA / ACCESSWIRE / July 31, 2024 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced the appoint...
More Protagonist Therapeutics, Inc. News

Company Profile

Protagonist Therapeutics, Inc. engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Head office United States
CEO Dinesh Patel
Employees 112
Founded 2006
Website www.protagonist-inc.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today